Invasive Non- Aspergillus Mold Infections in Transplant Recipients, United States, 2001–2006

1Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.

2This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

3Medscape, LLC designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

4All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at www.medscape.org/journal/eid; (4) view/print certificate.

5Release date: September 23, 2011; Expiration date: September 23, 2012

6Upon completion of this activity, participants will be able to:

7Distinguish the type of fungal infection most common in the current case series

8Evaluate patient characteristics associated with fungal infection after transplant

9Assess other factors associated with fungal infection after transplant

10Analyze the epidemiology of mucormycosis in the current case series

11Karen L. Foster, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Karen L. Foster has disclosed no relevant financial relationships.

12Charles P. Vega, MD, Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, has disclosed no relevant financial relationships.

13Disclosures: Benjamin J. Park, MD; Kathleen A. Wannemuehler, MSc; Janice M. Brown, MD; Lisa M. Brumble, MD; G. Marshall Lyon, MD, MMSc; Randall Walker, MD; Thomas J. Walsh, MD; and Dimitrios P. Kontoyiannis, MD, have disclosed no relevant financial relationships. Peter G. Pappas, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Pfizer Inc., Merck & Co., Inc., Astellas Pharma, Inc.; received grants for clinical research from Pfizer Inc., Merck & Co., Inc., Astellas Pharma, Inc. Barbara D. Alexander, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for bioMerieux, Bristol-Myers Squibb Company, Becton-Dickinson; received grants for clinical research from Pfizer Inc., Astellas Pharma, Inc., Charles River Laboratories. Elias J. Anaissie, MD, has disclosed the following relevant financial relationships: received grants for clinical research from Astellas Pharma, Inc., Millenium, Pfizer Inc. David R. Andes, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Pfizer Inc., Merck & Co., Inc., Astellas; received grants for clinical research from Merck, Astellas Pharma, Inc. John W. Baddley, MD, MSPH, has disclosed the following relevant financial relationships: served as an advisor or consultant for Pfizer Inc., Merck & Co., Inc., Abbott; received grants for clinical research from Pfizer Inc. Alison G. Freifeld, MD, has disclosed the following relevant financial relationships: received grants for clinical research from Streck Inc., Chimerix. Susan Hadley, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Merck & Co., Inc.; DSMB member. Loreen Herwaldt, MD, has disclosed the following relevant financial relationships: received grants for clinical research from 3M. James I. Ito, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Sigma Tau; served as a speaker or a member of a speakers bureau for Astellas Pharma, Inc., Merck & Co., Inc., Pfizer Inc. Carol A. Kauffman, MD, has disclosed the following relevant financial relationships: received grants for clinical research from Merck & Co., Inc.; chair for the Data Adjudication Committee for Phase IV anidulafungin trial (Pfizer Inc.). Kieren A. Marr, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Pfizer Inc., Merck & Co., Inc., Astellas Pharma, Inc.; received grants for clinical research from Merck & Co., Inc., Astellas Pharma, Inc. Vicki A. Morrison, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Amgen Inc., Celgene Corporation; served as a speaker or a member of a speakers bureau for Amgen Inc., Celgene Corporation, Genentech Inc., Pfizer Inc. Genovefa Papanicolaou, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Chimerix Inc., Merck & Co., Inc. Thomas F. Patterson, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Pfizer Inc., Merck & Co., Inc., Astellas Pharma, Inc., Basilea & Toyon; served as a speaker for Pfizer Inc.; received grants for clinical research from Pfizer Inc., Merck & Co., Inc., Astellas Pharma, Inc., Basilea, Schering-Plough Corporation. Trish M. Perl, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Hospira, BioMerieux, Pfizer Inc.; received grants for clinical research from Merck & Co., Inc., Sage. Mindy G. Schuster, MD, has disclosed the following relevant financial relationships: received grants for clinical research from Merck & Co., Inc. John R. Wingard, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Merck & Co., Inc.; served as a speaker or a member of a speakers bureau for Pfizer Inc.